COVID-19 vaccine trials

By: Ryan Wolfe / July 15, 2020

To combat COVID-19, Moderna launched a Phase 1 study consisting of 45 participants in an effort to create a vaccine on an expedited timeline. March 16th was the start of the Phase 1 testing. The initial group of 45 people were divided into groups of 15 individuals.   Each grouping received 2 doses of treatment, but each group received a different dosage of the proposed vaccine (25, 100, or 250 microgram dosages). The subjects who received both doses, showed higher levels of virus-defeating antibodies when compared to individuals who had recovered from the coronavirus. The majority of participants who received both dosages did report adverse reactions, as to be expected during the trials.

moderna

Given the results of Phase 1 trials by Moderna, Phase 2 trials are expected to begin any day now. Phase 2 will be expanded to 600 participants and will be conducted in much of the same way that Phase 1 was. Moderna President Steven Hoge told ‘CBS This Morning’ that "Our goal is to have a vaccine available for broad distribution by year-end or early next year." This is key to keep in the forefront of everyone’s mind, as it provides some tangible data towards the possibility of returning to “normalcy” in just a few months. This news is welcomes since recently many states, particularly in the south and southwest have seen an increase in COVID-19 cases, likely due to the relaxed social distancing practices. If the Moderna vaccine continues to have success in its trials and we maintain social distance, we could increase the chances of getting back to “normalcy” much quicker.

 

 

https://www.jpost.com/health-science/moderna-phase-1-results-show-covid19-vaccine-safe-induces-immune-response-635079

https://www.cbsnews.com/news/coronavirus-vaccine-moderna-testing-final-phase/

photo compliments of Getty Images

 


Categories: 2020, Virus, production, COVID-19, clinical trial, vaccine, study, vaccination, coronavirus, social distance, flatten the curve, health, participants, Moderna, pharmaceuticals, 2021, year end, CBS, trial, test subjects, subjects, science, antibody, Phase 1, phase 2


Ryan Wolfe

Written by

Ryan Wolfe

I am a proud Guttman Energy sales representative, who has a thirst of knowledge for the industry. I come from a strict, service based, industry that allows me to put my customer needs first. I look forward to utilizing my passion and past experience to help bolster my client’s operations. I take a personal pride in anything I do.


Guttman Energy Daily Market Update Disclaimer – The information contained in this market update is derived from sources believed to be reliable; however this update could include technical inaccuracies or typographical errors and Guttman Energy does not guarantee the accuracy, completeness or reliability of this update. FURTHERMORE, THIS UPDATE IS PROVIDED "AS IS," WHERE IS, WITH ALL FAULTS AND WITHOUT ANY WARRANTY OR CONDITION OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY. GUTTMAN ENERGY ALSO SPECIFICALLY DISCLAIMS ALL EXPRESS AND IMPLIED WARRANTIES. YOU USE THIS UPDATE AT YOUR SOLE RISK. This update and any view or comment expressed herein are provided for informational purposes only and should not be interpreted in any way as recommendation or inducement to buy or sell products, commodity futures or options contracts.


Comments

Subscribe to our blog

Price Feed

Stay up-to-date on current fuel prices and market trends with our NYMEX price feed (15 minute delay to the live market).

© 2018 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.

Categories

Contact Us